Skip to main content

View full-text article in PMC

. 2011 Aug 4;30(1):72. doi: 10.1186/1756-9966-30-72

Table 2.

Summary RRs and 95% CI

Complications	ZOL vs no ZOL			Upfront ZOL vs delayed ZOL
	RR (95%CI)	P^⋆	Number of studies	RR (95%CI)	P^⋆	Number of studies
Arthralgia	1.162 (1.096-1.232)^#	0.466	4	1.022 (0.932-1.120)	0.850	3
Bone pain	1.257 (1.149-1.376)	0.193	2	1.284 (1.135-1.453)	0.460	2
Muscle pain	1.198 (0.901-1.594)	0.366	2	1.071 (0.942-1.217)	0.422	3

RR, risk ratio; CI, confidence interval; ZOL, zoledronic acid;

*P value for between-study heterogeneity; #the number in AZURE trial included the number of arthralgia and muscle pain.